Experienced in Malnutrition

Eiju Negoro

Matsuoka, JP 
Experienced in Malnutrition
Matsuoka, JP 
OverviewLocationsClinical Research

Overview

Eiju Negoro practices in Matsuoka, Japan. Negoro is rated as an Experienced expert by MediFind in the treatment of Malnutrition. Their top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Lymphomatoid Granulomatosis.

Their clinical research consists of co-authoring 40 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Malnutrition.

Locations

Matsuoka, 9101193, Japan
Other Locations
Japan
Yoshida, 9101193, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Bendamustine, Rituximab
Study Phase: Phase 3
View 1 Less Clinical Trial

40 Total Publications

Clinical Impact of the Geriatric Nutritional Risk Index on Chemotherapy-Related Adverse Events in Diffuse Large B-Cell Lymphoma: A Multicenter Study.
Clinical Impact of the Geriatric Nutritional Risk Index on Chemotherapy-Related Adverse Events in Diffuse Large B-Cell Lymphoma: A Multicenter Study.
Journal: Nutrients
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Negoro's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile